SUTRO BIOPHARMA, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
STRO$9.62+4.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations
(In thousands, except share and per share amounts)
| Three Months Ended · Six Months Ended | ||||
|---|---|---|---|---|
| June 30, | June 30, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Revenue | $63,745 | $25,706 | $81,144 | $38,714 |
| Operating expenses | ||||
| Research and development | 38,325 | 62,020 | 89,922 | 118,898 |
| General and administrative | 10,343 | 12,371 | 23,616 | 25,092 |
| Restructuring and related costs | 18,422 | — | 39,465 | — |
| Total operating expenses | 67,090 | 74,391 | 153,003 | 143,990 |
| Loss from operations | (3,345) | (48,685) | (71,859) | (105,276) |
| Interest income | 2,519 | 4,911 | 5,708 | 9,007 |
| Unrealized gain on equity securities | — | 4,808 | — | 8,487 |
| Non-cash interest expense related to the sale of future royalties | (9,647) | (7,286) | (18,991) | (14,470) |
| Interest and other income (expense), net | (1,044) | (1,758) | (2,336) | (3,971) |
| Loss before provision for income taxes | (11,517) | (48,010) | (87,478) | (106,223) |
| (Benefit) from / provision for income taxes | (18) | 8 | (11) | 8 |
| Net loss | $(11,499) | $(48,018) | $(87,467) | $(106,231) |
| Net loss per share, basic and diluted | $(0.14) | $(0.59) | $(1.04) | $(1.49) |
| Weighted-average shares used in computing basic and diluted net loss per share | 84,580,125 | 81,224,628 | 83,846,892 | 71,341,211 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.